What does a serum iron of 32 µg/dL with a transferrin saturation of 12% indicate and how should it be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Iron Deficiency with Low Transferrin Saturation

Your patient has confirmed iron deficiency that requires immediate treatment, as indicated by a transferrin saturation of 12%—well below the diagnostic threshold of 16-20%—combined with a serum iron of 32 µg/dL. 1

Diagnostic Interpretation

Your laboratory values definitively establish iron-deficient erythropoiesis:

  • TSAT of 12% is diagnostic for absolute iron deficiency in adults without inflammation (threshold <16%) and remains diagnostic even in inflammatory conditions (threshold <20%). 1
  • Serum iron of 32 µg/dL is markedly low, confirming inadequate iron availability for red blood cell production. 1
  • The combination of low serum iron with low TSAT indicates the bone marrow lacks sufficient available iron to synthesize hemoglobin, regardless of total body iron stores. 1

Critical next step: You must obtain a serum ferritin level to distinguish between absolute and functional iron deficiency, as this fundamentally changes your treatment approach. 1

Complete Your Diagnostic Work-Up Immediately

Essential Laboratory Tests (Order Within 1 Week)

  • Serum ferritin – This is the single most important missing value. 1

    • If ferritin <30 ng/mL → absolute iron deficiency
    • If ferritin 30-100 ng/mL → likely mixed picture
    • If ferritin 100-300 ng/mL with TSAT <20% → functional iron deficiency 1

  • Complete blood count with hemoglobin, hematocrit, MCV, and reticulocyte count to assess anemia severity and red cell indices. 1

  • C-reactive protein to identify chronic inflammation that would alter ferritin interpretation and treatment choice. 1

  • Renal function (creatinine, eGFR) because chronic kidney disease profoundly influences iron metabolism and mandates different treatment thresholds. 1

Mandatory Evaluation for Blood Loss

  • In men and postmenopausal women: Gastrointestinal investigation with colonoscopy and upper endoscopy is mandatory to exclude occult malignancy as a source of chronic blood loss. 1

  • In premenopausal women: Assess menstrual blood loss patterns to identify gynecologic sources. 2

  • Additional considerations: Dietary insufficiency, malabsorption (celiac disease, inflammatory bowel disease), NSAID use, frequent blood donation, or high-impact athletic activity causing hemolysis. 1

Treatment Algorithm Based on Ferritin Results

Scenario 1: Ferritin <30 ng/mL (Absolute Iron Deficiency Without Inflammation)

Start oral iron supplementation:

  • Elemental iron 100-200 mg daily in divided doses (e.g., ferrous sulfate 325 mg = 65 mg elemental iron, taken 2-3 times daily). 1
  • Alternate-day dosing improves absorption and reduces gastrointestinal side effects compared with daily dosing. 1
  • Common adverse effects include constipation, diarrhea, and nausea. 1

Target goals:

  • Ferritin ≥30-45 ng/mL and TSAT ≥20%. 1
  • Hemoglobin should increase by 1-2 g/dL within 4-8 weeks of treatment initiation. 1

Recheck iron studies at 8-10 weeks after starting oral iron. 1

Scenario 2: Ferritin 30-100 ng/mL with TSAT 12% (Mixed Picture)

This suggests a combination of true iron deficiency and possible early inflammation. 1

  • Trial of oral iron is reasonable if CRP is normal.
  • Switch to IV iron if CRP is elevated or if no hemoglobin response after 8-10 weeks of adequate oral therapy. 1

Scenario 3: Ferritin 100-300 ng/mL with TSAT 12% (Functional Iron Deficiency)

This is functional iron deficiency—iron is sequestered in storage sites by hepcidin and unavailable for erythropoiesis despite "normal" ferritin. 1

Oral iron is ineffective and should NOT be used because hepcidin blocks intestinal iron absorption in inflammatory states. 1

Intravenous iron is mandatory:

  • Preferred formulations: Ferric carboxymaltose, iron sucrose, or low-molecular-weight iron dextran. 1
  • Dosing example: Ferric carboxymaltose 1 g IV over 15 minutes as a single dose, or iron sucrose 100 mg IV at sequential dialysis sessions (if on hemodialysis). 1, 3
  • IV iron bypasses hepcidin-mediated intestinal blockade and directly delivers iron to bone marrow. 1

Target goals:

  • Ferritin ≥100 ng/mL and TSAT ≥20%. 1

Recheck iron studies 4-8 weeks after the last IV iron infusion—do NOT measure within 4 weeks because circulating iron interferes with assay accuracy. 1

Scenario 4: Ferritin >300 ng/mL with TSAT 12% (Severe Functional Deficiency)

This indicates severe inflammation with profound iron sequestration. 1

  • IV iron is required as first-line therapy. 1
  • Consider erythropoiesis-stimulating agents (ESAs) if no response to IV iron alone, particularly in chronic kidney disease or heart failure. 1
  • Maintain TSAT >20% during ESA therapy to ensure sufficient iron availability for red cell production. 1

Common Diagnostic Pitfalls to Avoid

  • Do not rely on serum iron alone—it has high intra-individual variability, diurnal fluctuations, and post-prandial changes; normal serum iron does not exclude iron deficiency. 1

  • Do not interpret ferritin without TSAT—ferritin is an acute-phase reactant and can be falsely elevated in inflammation, masking true iron deficiency. 1

  • Do not measure iron parameters within 4 weeks of IV iron infusion—circulating iron yields falsely elevated results. 1

  • Do not use oral iron in functional iron deficiency with active inflammation—it is ineffective because hepcidin blocks intestinal absorption. 1

  • Do not assume elevated ferritin means iron overload in inflammatory states—it actually reflects inflammation-driven iron sequestration. 1

When to Consider IV Iron Regardless of Ferritin

Specific indications for intravenous iron include: 1

  • Chronic kidney disease with eGFR <30 mL/min/1.73 m²
  • Heart failure (NYHA class II-III) with ferritin <100 ng/mL or ferritin 100-300 ng/mL plus TSAT <20%
  • Active inflammatory bowel disease
  • Intolerance to oral iron (nausea, constipation)
  • Lack of response after 4-8 weeks of adequate oral therapy
  • Documented malabsorption
  • Ongoing blood loss that exceeds oral replacement capacity

Monitoring Response to Treatment

  • If oral iron: Recheck hemoglobin at 4 weeks—expect 1-2 g/dL increase. If no response, consider malabsorption, continued bleeding, or switch to IV iron. 2

  • If IV iron: Recheck CBC and iron parameters (ferritin, TSAT) at 4-8 weeks after the last infusion. 1

  • If using ESAs: Maintain TSAT >20% throughout therapy to optimize dose-response. 1

References

1
Guideline

Iron Saturation Measurement and Interpretation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

2
Research

Iron deficiency anemia.

American family physician, 2007

Related Questions

What is the most likely cause of a normocytic anemia with normal serum iron, normal total iron‑binding capacity, and low transferrin saturation, and how should it be evaluated and managed?
At what level of iron deficiency, specifically serum ferritin and transferrin saturation, is an iron transfusion indicated in a patient with iron deficiency anemia?
Can iron supplements be given to patients with elevated ferritin (iron storage protein) levels?
What does a low transferrin saturation coefficient indicate and how is it managed?
In a patient with normal hemoglobin and hematocrit, low serum iron, low transferrin saturation, and a ferritin level of 62 µg/L (within normal range), should iron supplementation be started?
In a 52-year-old man with uncontrolled diabetes, recent right middle cerebral artery infarction, on metformin (Trajenta), empagliflozin (Jardiance), clopidogrel (Coplavix), and a statin, who had two episodes of ketoacidosis (first with hyperglycemia, second with tachycardia and severe hypertension), what other possible etiologies should be considered and what are the next steps in management?
What is the appropriate treatment for a patient with a red‑cell distribution width of 17.2 % and a mean corpuscular volume of 87.2 fL?
In a child who received measles‑mumps‑rubella (MMR) vaccine at 8 months, 12 months, and 4 years, is the 8‑month dose ineffective and are the 12‑month and 4‑year doses fully effective as if the early dose had not been given?
Which clinical signs and laboratory thresholds require temporary discontinuation of lisinopril (ACE inhibitor), spironolactone (potassium‑sparing diuretic), furosemide (loop diuretic), and hydrochlorothiazide (thiazide diuretic) to avoid renal injury, electrolyte disturbances, or hypotension?
Is an elevated hemoglobin A1c a risk factor for patients undergoing venous interventions (e.g., venous stenting, angioplasty, thrombectomy, or varicose‑vein procedures)?
How should Lotemax (loteprednol etabonate) 0.5% ophthalmic suspension be dosed and monitored for postoperative ocular inflammation, and what are its contraindications and alternative therapies?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question